Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results

The latest update is out from Armata Pharmaceuticals ( (ARMP) ).

On May 19, 2025, Armata Pharmaceuticals announced positive topline results from its Phase 1b/2a diSArm trial, which evaluated the intravenous administration of AP-SA02 for treating complicated Staphylococcus aureus bacteremia. The study met all primary endpoints for safety, tolerability, and clinical response, showing significant improvement in clinical outcomes and prevention of relapse compared to best available antibiotic therapy. The trial’s success marks a significant advancement in phage therapy, with no serious adverse events reported, and supports further development towards a pivotal trial. Armata’s ability to produce high-purity phage therapeutics and its manufacturing capacity to produce over 10,000 full courses annually positions it strongly in the field of bacteriophage-based treatments.

The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Underperform.

Armata Pharmaceuticals is currently struggling with severe financial issues, including negative revenue growth and a weak balance sheet. Technical indicators suggest bearish momentum, and the valuation metrics are unattractive due to negative earnings. Although the recent $10M loan for clinical trials is a positive step, it does not substantially change the company’s precarious financial position.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing a broad pipeline of natural and synthetic phage candidates, including those targeting Pseudomonas aeruginosa and Staphylococcus aureus, with in-house phage-specific current Good Manufacturing Practices (cGMP) manufacturing capabilities.

Average Trading Volume: 16,986

Technical Sentiment Signal: Sell

Current Market Cap: $48.86M

Find detailed analytics on ARMP stock on TipRanks’ Stock Analysis page.